Pacemaker Arrhythmia-Detection AI Patent Landscape
The pacemaker arrhythmia-detection AI field is highly concentrated, with two legacy medical-device incumbents — Pacesetter and Medtronic — commanding the majority of activity among the top hundred filers. Annual filing volume has eased materially from its 2017 peak, placing this field in a decline stage and signalling that foundational IP positions are mature while digital-signal-processing and healthcare-informatics branches remain comparatively sparse.
Two incumbents dominate a highly concentrated field
Pacesetter Inc leads all applicants by patent records, followed closely by Medtronic Inc, with Cardiac Pacemakers Inc a distant third. Together, these three account for the bulk of activity among ranked filers, reflecting a field shaped by a small number of large medical-device companies rather than a broad competitive ecosystem.
The top five filers hold 75% of the combined total of the hundred largest filers — a concentration level that indicates significant barriers to repositioning through incremental IP accumulation. The tier gap between rank one and rank four is substantial, suggesting that challengers would need differentiated technical approaches, not volume, to establish meaningful IP positions.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Pacesetter Inc | 112 | |
| 2 | Medtronic Inc | 97 | |
| 3 | Cardiac Pacemakers Inc | 26 | |
| 4 | Atacor Medical Inc | 17 | |
| 5 | Galvani | 12 | |
| 6 | EBR Systems Inc | 5 | |
| 7 | Telectronics | 5 | |
| 8 | Imperception Inc | 4 | |
| 9 | University Health Network | 4 | |
| 10 | Sigmed | 4 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | St. Jude Medical AB | 3 | |
| 12 | SoftMax Inc | 3 | |
| 13 | Impulse Dynamics NV | 3 | |
| 14 | Hakki A. Hadi | 2 | |
| 15 | Jung Tzyy-Ping | 2 | |
| 16 | Hakki A. Hamid | 2 | |
| 17 | Troy E. Jackson | 2 | |
| 18 | Draeger Medical Systems Inc | 2 | |
| 19 | Boston Scientific Neuromodulation Corp | 2 | |
| 20 | Walter H. Olson | 2 |
Pacesetter and Medtronic’s dominance in electrotherapy and cardiac-monitoring classifications implies that the core detection and stimulation IP space is well-defended. New entrants and challengers will find more room in adjacent digital-processing, remote-transmission, and healthcare-informatics branches where incumbent filing density is lower.
The most recent 18–24 months of filings are subject to publication lag and will appear under-counted in this snapshot; conclusions about very recent activity should be treated with caution. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Peak activity in 2017; electrotherapy IPC class dominates the technology mix
The annual trend chart and the technology-composition breakdown together reveal a field that built its foundational IP base early and has since settled into a lower-volume, mature phase, with one classification accounting for the overwhelming majority of filings.
Annual filing trend
Annual filings peaked in 2017 and have trended lower since, consistent with the field’s decline lifecycle stage. The most recent two years (2025–2026) should be read as partial counts due to publication lag rather than a definitive signal of direction.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy and radiation therapy) is the dominant classification by a wide margin, reflecting the field’s core focus on implantable stimulation and detection hardware. A61B (Diagnosis and surgery) is a meaningful secondary branch, while G06F (digital data processing), H04B (transmission), and G16H (healthcare informatics) each account for a small share — flagging those as under-served adjacent areas.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Pacemaker having adaptive arrhythmia detection win…
Methods for improving detection of arrhythmias by adaptively increasing arrhythmia detection intervals. One method includes increasing the V2V, the overall cardiac cycle length, thereby decreasing the pacing rate in the presence of ventricular safety paces (VSPs). Another method includes shortening the trigger interval following the atrial pace event… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Antiarrhythmia pacer using antiarrhythmia pacing a… | 1,115 |
| 2 | Apparatus and method employing plural electrode co… | 759 |
| 3 | Apparatus and method for generation of varying wav… | 519 |
| 4 | Method and apparatus for discriminating among norm… | 406 |
| 5 | Apparatus and method for detecting abnormal cardia… | 398 |
| 6 | Method and apparatus for diagnosis and treatment o… | 298 |
| 7 | Automatic implantable pulse generator | 278 |
| 8 | Sympathetic nerve stimulator and/or pacemaker | 258 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D prioritisation
Four structural dimensions — maturity, concentration, collaboration, and geography — shape the strategic options available to teams entering or expanding in this space.
Decline stage: foundational IP is set
The lifecycle evidence places this field in a decline stage, with annual volume easing from its 2017 peak. Core detection and stimulation claims are well-established, meaning incremental improvements to classical algorithms are unlikely to yield defensible new IP. R&D investment is better directed at underexplored technical routes such as AI-model-based inference (G06N) or remote monitoring integration.
Decline stageTop five hold 75% of the largest-filer pool
The top five filers account for 75% of the combined total of the hundred largest filers, a level of concentration that makes head-to-head filing strategies inefficient for new entrants. Niche specialisation — particularly in digital-signal processing, biotelemetry, or AI-model sub-classes — offers a more accessible entry path than competing directly in core electrotherapy classifications.
High concentrationNo co-filing activity detected in this corpus
The collaboration evidence shows no recorded co-applicant filings within the current dataset. This absence may reflect the proprietary, competitive nature of implantable-device IP, where incumbents rarely share claims with external partners. It also means that collaborative or open-innovation strategies would face an unusual landscape with no precedent to benchmark against.
Evidence pendingUS-centric, with meaningful EPO and PCT coverage
The United States is the lead jurisdiction by patent records, followed by the European Patent Office and WIPO PCT filings. Canada and Australia hold modest positions. China has very limited coverage in this corpus, which may reflect either filing strategy or scope of the dataset — teams assessing Asia-Pacific freedom-to-operate should conduct a dedicated search.
US-ledGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
Pacesetter and Medtronic set the competitive benchmark; Atacor is the only tracked new entrant
Two legacy medical-device companies define the upper tier of this landscape. A single new entrant — Atacor Medical — is the only other applicant with a tracked recent-period trajectory, suggesting very limited new challenger activity.
Pacesetter Inc
Pacesetter leads with 112 patent records, concentrated in A61N 1 (Electrotherapy) and A61B 5 (Diagnosis and surgery), with a secondary presence in H04B 13 (Transmission). Recent-period momentum shows a 57% decline versus the prior three-year window, consistent with the field’s overall maturation. The breadth of its transmission-class filings is a differentiator not replicated by most other top filers.
families: 112Atacor Medical Inc
Atacor Medical holds 17 patent records and is the only applicant identified as a new entrant in the recent filing window, making it the sole source of fresh challenger activity in an otherwise declining field. Its filings are concentrated in A61N 1 and A61B 17, with an additional presence in A61M 25, suggesting a device-integration approach that spans stimulation, surgical access, and fluid-management hardware.
families: 17| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Pacesetter Inc | 6 | ▼ -57% |
| Atacor Medical Inc | 4 | ▲ new entrant |
Digital-processing and healthcare-informatics branches are under-served relative to core electrotherapy
Several IPC branches adjacent to the dominant A61N classification show low filing counts and low shares among records in scope, indicating areas where existing IP does not yet reflect the full technical potential of AI-driven arrhythmia detection.
G06F · Electric digital data processing
With only 11 patent records and a 2% share of the technology composition, the digital data processing branch is sparse relative to the volume of signal-processing work implicit in arrhythmia detection. Incumbents have not systematically claimed algorithmic or software-layer IP in this class. Teams with software-defined detection pipelines or embedded inference engines could file here with limited direct overlap against existing corpus positions. Entry path: claims focused on real-time signal classification firmware or embedded ML inference on device.
Search this in Eureka →G16H · Healthcare informatics
With only 5 patent records and a 1% share, healthcare informatics is the most under-represented branch with plausible clinical relevance. As arrhythmia-detection systems increasingly connect to remote monitoring platforms and clinical decision-support tools, claims covering data integration, patient-record linkage, and AI-assisted clinical alerting fall under G16H. No incumbent has established a material position here, making it the most accessible adjacent branch for organisations with connected-health capabilities.
Search this in Eureka →Frequently asked questions
The analysis covers 75 patent families. This is the foundational corpus from which trends, technology composition, and jurisdiction data are derived.
Pacesetter Inc leads with 112 patent records, followed by Medtronic Inc with 97 patent records and Cardiac Pacemakers Inc with 26 patent records.
The field is assessed as being in a decline stage. Annual filings peaked in 2017 and have eased since, indicating that foundational IP positions are mature and new filing activity is limited.
The United States is the primary jurisdiction by patent records, followed by the European Patent Office and WIPO PCT filings. Canada and Australia have modest coverage. China has very limited representation in this corpus.
G06F (Electric digital data processing) and G16H (Healthcare informatics) are the most under-served branches relative to the dominant A61N classification, with 11 and 5 patent records respectively. H04B (Transmission) and G05B (Control and regulating systems) are also sparse.
No co-applicant filings are recorded in the current dataset for this topic. The field appears to be driven by proprietary, single-applicant IP strategies, with no evidence of systematic cross-organisation collaboration.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.